{"brief_title": "A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia", "brief_summary": "A 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia", "detailed_description": "Study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from the Positive and Negative Syndrome Scale (PANSS).", "condition": ["Schizophrenia"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Lurasidone", "Placebo"], "description": ["80 mg AM dosing once daily", "Matching Placebo to 40mg lurasidone tablets"], "arm_group_label": ["Lurasidone", "Placebo"], "criteria": "Inclusion Criteria: - Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV - The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment - If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception Exclusion Criteria: - The patient has used an investigational drug within the past 30 days - The patient has participated in a previous study of this compound", "gender": "All", "minimum_age": "18 Years", "maximum_age": "64 Years", "healthy_volunteers": "No", "keyword": "Lurasidone", "mesh_term": ["Schizophrenia", "Lurasidone Hydrochloride"], "id": "NCT00088634"}